IFF lawsuit
This article was originally published in The Rose Sheet
Executive Summary
Fragrance supplier does not anticipate $20 mil. court decision "to have a material adverse effect" on its financial results, operating results or liquidity, IFF states after Missouri circuit court ruled against the company March 15. Court awarded $20 mil. in compensatory damages to a former employee of one of IFF's customers, who claimed he sustained respiratory damage in the workplace from the facility's use of a butter flavor supplied by IFF. Company plans to appeal the decision, stating the verdict is "not supported by the evidence or the law and should therefore be reversed." Plaintiff, however, is one of a number of employees who worked at the facility owned and operated by Gilster-Mary Lee Corporation in Jasper, Miss. that are suing IFF. Firm states the majority of plaintiffs claim to have sustained lesser respiratory injuries than the awarded plaintiff...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.